Stock ACTI ACTIVE BIOTECH AB
Add to a list
To use this feature you must be a member
Log inSign up

Active Biotech AB Stock

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.53 SEK -2.21% Intraday chart for Active Biotech AB -5.19% +16.10%
May. 22 Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug MT
May. 22 Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology CI

Financials

Sales 2024 * - Sales 2025 * 15.6M 1.49M Capitalization 192M 18.3M
Net income 2024 * -42M -4.01M Net income 2025 * -35M -3.34M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.3 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.39%
More Fundamentals * Assessed data

Chart Active Biotech AB

Dynamic Chart

Latest news about Active Biotech AB

Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug MT
Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology CI
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops CI
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024 CI
Active Biotech Raises SEK44 Million via Rights Offering MT
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops MT
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee CI
Active Biotech Plans SEK51 Million Rights Issue; Shares Sink MT
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023 CI
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod CI
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Press releases Active Biotech AB

Number of shares and votes in Active Biotech AQ
Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024 AQ
Annual General Meeting of Active Biotech AB AQ
Active Biotech acquires exclusive rights to patents of tasquinimod in combination therapy AQ
Active Biotech : Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech PU
More press releases

News in other languages on Active Biotech AB

IPSEN : nouveau paiement d'étape de 12 millions d'euros à Active Biotech pour le Tasquinimod
IPSEN : et Active Biotech achèvent le recrutement pour l'étude phase III avec tasquinimod
BNP PARIBAS : INDICES : Le CAC 40 réduit sa perte à la mi-journée
IPSEN : résultats positifs d'une étude sur le tasquinimod
IPSEN : les données de tolérance de tasquinimod présentées du 24 au 28 février
More news

Quotes and Performance

1 day-2.21%
1 week-5.19%
Current month-5.36%
1 month+3.11%
3 months+3.92%
6 months+8.27%
Current year+16.10%
More quotes

Highs and lows

1 week
0.52
Extreme 0.516
0.63
1 month
0.47
Extreme 0.473
0.63
Current year
0.43
Extreme 0.4335
1.48
1 year
0.40
Extreme 0.4005
1.48
3 years
0.40
Extreme 0.4005
1.56
5 years
0.40
Extreme 0.4005
4.31
10 years
0.40
Extreme 0.4005
35.60
More quotes

Managers and Directors - Active Biotech AB

Managers TitleAgeSince
Helén Tuvesson CEO
 Chief Executive Officer 62 97-12-31
Hans Kolam DFI
 Director of Finance/CFO 73 99-12-31
Erik Vahtola CTO
 Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Uli Alf Hacksell BRD
 Director/Board Member 74 19-05-22
Aleksandar Danilovski BRD
 Director/Board Member 50 19-12-31
Michael Shalmi CHM
 Chairman 59 19-05-22
More insiders

Quotes

Date Price Change Volume
24-06-10 0.53 -2.21% 119,305
24-06-07 0.542 -4.91% 660,091
24-06-05 0.57 -4.36% 1,022,846
24-06-04 0.596 +6.62% 1,173,464

Delayed Quote Nasdaq Stockholm, June 10, 2024 at 12:00 pm EDT

More quotes

Company Profile

Active Biotech AB (publ) is a Sweden-based Company, which develops pharmaceutical products within medical areas where the immune defense is important, including cancer and inflammatory diseases. The project portfolio comprises both small, orally active immunomodulatory molecules and antibody-based immunotherapy.
Sector
Biotechnology & Medical Research
Calendar
2024-08-22 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTIVE BIOTECH AB Stock Active Biotech AB
+16.10% 18.61M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.77% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.05% 108B
BIONTECH SE Stock BioNTech SE
-7.16% 24.21B
ARGENX SE Stock argenx SE
+2.07% 22.78B
GENMAB A/S Stock Genmab A/S
-10.79% 17.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.47% 16.37B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.23% 13.58B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.13% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ACTI Stock